| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $0 | 0 | – |
Sells | $0 | 0 | – |
Jade Biosciences, Inc. operates as a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases. It develops JADE101, a monoclonal antibody to block the A PRoliferation Inducing Ligand protein, which is in phase 1 clinical trial. The company also develops JADE201 and JADE-003, which are in preclinical development stage. Jade Biosciences, Inc. has a collaboration agreement with Paragon Therapeutics, Inc. Jade Biosciences, Inc. is based in Waltham, Massachusetts.
Over the last 12 months, insiders at Jade Biosciences, Inc. have bought $0 and sold $0 worth of Jade Biosciences, Inc. stock.
On average, over the past 5 years, insiders at Jade Biosciences, Inc. have bought $44,400 and sold $0 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 6,000 shares for transaction amount of $44,400 was made by Frohlich Tom (Chief Executive Officer) on 2025‑05‑16.
| Frohlich Tom | Chief Executive Officer | 6000 0.0094% | $87,420.00 | 1 | 0 | +49.8% |
$100,473,344 | 83 | 9.53% | $826.91M | |
$15,410,062 | 81 | 39.69% | $975.93M | |
$5,911,307 | 70 | -1.38% | $884.8M | |
$11,663,618 | 57 | 32.20% | $934.29M | |
$129,396,927 | 18 | 48.82% | $825.26M |
| Increased Positions | 76 | +131.03% | 20M | +64.56% |
| Decreased Positions | 22 | -37.93% | 5M | -15.88% |
| New Positions | 33 | New | 10M | New |
| Sold Out Positions | 8 | Sold Out | 4M | Sold Out |
| Total Postitions | 112 | +93.1% | 47M | +48.68% |